What is the 13F Pro Quality Score for NSPR?

13F Pro ranks InspireMD, Inc. (NSPR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NSPR's current score at https://13fpro.ai/company/NSPR (free sign-up required for the full ranking).

Which hedge funds own the most NSPR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NSPR include Rosalind Advisors,, abrdn plc, Nantahala Capital Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/NSPR as soon as new 13F filings post.

Where does 13F Pro source NSPR data?

All InspireMD, Inc. fundamentals and ownership data come directly from SEC EDGAR. InspireMD, Inc. files with the SEC under CIK 1433607. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NSPR in?

InspireMD, Inc. (NSPR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NSPR research updated on 13F Pro?

NSPR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

InspireMD, Inc.(NSPR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1433607 NSPR stock profile & AI dashboard →

13F Pro Quality Score

25.1/100

Rank #2,673 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why NSPR Scores 25/100

exact factor attribution · 2026-09-11

NSPR's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+7.3 pts

86th pct

Institutional flow

-1.8 pts

14th pct

Earnings quality

-2.0 pts

30th pct

Earnings growth

-2.2 pts

5th pct

Shareholder dilution

-2.3 pts

5th pct

Capital efficiency

-4.8 pts

3th pct

Scale

-6.3 pts

8th pct

Profitability

-6.4 pts

8th pct

Free cash flow

-6.5 pts

7th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

NSPR Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for InspireMD, Inc. (NSPR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NSPR at 25.1/100 on a 32-signal composite quality model, placing it at rank #2,673 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), InspireMD, Inc. reports quarterly revenue of $1.8M, net income of $-14.3M, free cash flow of $-11.2M. Top institutional holders of NSPR by reported 13-F value include Rosalind Advisors, abrdn plc, Nantahala Capital Management, based on the most recent SEC filings. NSPR trades on the Nasdaq exchange and files with the SEC under CIK 1433607. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NSPR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for InspireMD, Inc. directly from SEC EDGAR. InspireMD, Inc.'s 13F Pro composite quality score has ranged between 25 and 27 since 2026, currently 25.1 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about InspireMD, Inc.

Quirks, history, and lore behind NSPR — the kind of stuff that makes a stock memorable.

1
The Basics
A medical device company · small-cap · dual presence in Israel and the United States · listed on a U.S. exchange.
2
The Numbers
Annual revenue in the low tens of millions of dollars — classic early-stage med-tech — with a market cap that has spent considerable time well under $100 million.
3
The History
Founded in the late 2000s, the company was built around a single bold idea: reinvent the carotid artery stent to dramatically cut stroke risk during the procedure itself.
4
The Secret
Its flagship device wraps a stent in a mesh embolic protection system — the shield is built right in, so clots can't escape into the brain during deployment.
5
The Lore
The company scored a significant win when the FDA cleared its CGuard system for the U.S. market, years after it had already gained traction in Europe.
6
The Giveaway
Its ticker spells out NSPR and its name literally tells you what it does: inspire better outcomes in neurovascular and cardiovascular care, one protected stent at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$1.8M

Net Income

Q2 2026

$-14.3M

Free Cash Flow

Q2 2026

$-11.2M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+28.1% YoY

$9.0MFY 2025

FY22 $5.2MFY23 $6.2MFY24 $7.0MFY25 $9.0M

Net Income

-52.4% YoY

$-48.8MFY 2025

FY22 $-18.5MFY23 $-19.9MFY24 $-32.0MFY25 $-48.8M

Operating Income

-48.1% YoY

$-49.6MFY 2025

FY22 $-18.7MFY23 $-21.1MFY24 $-33.5MFY25 $-49.6M

EPS (Diluted)

+0.0% YoY

$-0.76FY 2025

FY22 $-2.35FY23 $-0.82FY24 $-0.76FY25 $-0.76

Total Assets

+48.3% YoY

$69.4MFY 2025

FY22 $24.7MFY23 $47.6MFY24 $46.8MFY25 $69.4M

Op. Cash Flow

-60.5% YoY

$-35.1MFY 2025

FY22 $-15.5MFY23 $-16.4MFY24 $-21.9MFY25 $-35.1M

Free Cash Flow

-58.0% YoY

$-36.8MFY 2025

FY22 $-16.0MFY23 $-16.8MFY24 $-23.3MFY25 $-36.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$9.0M +28.1%	$7.0M +13.0%	$6.2M +20.0%	$5.2M +15.0%	$4.5M +80.9%	$2.5M
Net Income	$-48.8M -52.4%	$-32.0M -60.7%	$-19.9M -7.7%	$-18.5M -24.0%	$-14.9M -41.5%	$-10.5M
Operating Income	$-49.6M -48.1%	$-33.5M -58.5%	$-21.1M -13.0%	$-18.7M -27.2%	$-14.7M -41.8%	$-10.4M
EPS (Diluted)	$-0.76 +0.0%	$-0.76 +7.3%	$-0.82 +65.1%	$-2.35	—	—
Total Assets	$69.4M +48.3%	$46.8M -1.8%	$47.6M +93.3%	$24.7M -37.9%	$39.7M +123.4%	$17.8M
Operating Cash Flow	$-35.1M -60.5%	$-21.9M -33.5%	$-16.4M -5.4%	$-15.5M -17.7%	$-13.2M -45.5%	$-9.1M
Free Cash Flow	$-36.8M -58.0%	$-23.3M -38.9%	$-16.8M -4.6%	$-16.0M -18.2%	$-13.6M -47.8%	$-9.2M

Get alerted when NSPR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for InspireMD, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NSPR

Rosalind Advisors, Inc.
$2.7M3,905,743 sh
abrdn plc
$2.6M3,698,364 sh
Nantahala Capital Management, LLC
$2.4M3,376,484 sh
ORBIMED ADVISORS LLC
$2.2M3,133,405 sh
Parkman Healthcare Partners LLC
$1.7M2,416,518 sh
MARSHALL WACE, LLP
$1.3M1,860,405 sh
Soleus Capital Management, L.P.
$732.1K1,045,708 sh
PURA VIDA INVESTMENTS, LLC
$315.4K450,517 sh
INGALLS & SNYDER LLC
$258.0K368,800 sh
Affiance Financial, LLC
$175.3K250,370 sh

Fund	Value	Shares
Rosalind Advisors, Inc.	$2.7M	3,905,743
abrdn plc	$2.6M	3,698,364
Nantahala Capital Management, LLC	$2.4M	3,376,484
ORBIMED ADVISORS LLC	$2.2M	3,133,405
Parkman Healthcare Partners LLC	$1.7M	2,416,518
MARSHALL WACE, LLP	$1.3M	1,860,405
Soleus Capital Management, L.P.	$732.1K	1,045,708
PURA VIDA INVESTMENTS, LLC	$315.4K	450,517
INGALLS & SNYDER LLC	$258.0K	368,800
Affiance Financial, LLC	$175.3K	250,370

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NSPR on your watchlist

Track score changes the day InspireMD, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NSPR a good stock to buy?

13F Pro's AI-powered analysis of InspireMD, Inc. (NSPR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NSPR are available on the NSPR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NSPR is classified as a small company.

Which hedge funds own NSPR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NSPR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of InspireMD, Inc.'s investment landscape.